These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36232632)

  • 21. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
    Vaduganathan M; Jhund PS; Claggett BL; Packer M; Widimský J; Seferovic P; Rizkala A; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Eur Heart J; 2020 Jul; 41(25):2356-2362. PubMed ID: 32221596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
    JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
    Halle M; Schöbel C; Winzer EB; Bernhardt P; Mueller S; Sieder C; Lecker LSM
    Eur J Heart Fail; 2021 Dec; 23(12):2073-2082. PubMed ID: 34591356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
    Berardi C; Braunwald E; Morrow DA; Mulder HS; Duffy CI; O'Brien TX; Ambrosy AP; Chakraborty H; Velazquez EJ; DeVore AD;
    JACC Heart Fail; 2020 Oct; 8(10):859-866. PubMed ID: 32919915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
    Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
    JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
    J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
    Maggioni AP; Clark AL; Barrios V; Damy T; Drozdz J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Zeymer U;
    ESC Heart Fail; 2022 Dec; 9(6):4209-4218. PubMed ID: 36106548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.
    Zhang R; Sun X; Li Y; He W; Zhu H; Liu B; Zhang A
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211058681. PubMed ID: 34994233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.